Pune-based Enzene Biosciences has launched the Ranibizumab the seventh biosimilar a recombinant Fab used as a treatment for neovascular age-related macular degeneration (AMD). The company further stated that it is actively progressing with the development of three additional biosimilars in various stages.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment